Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently?
ObjectiveAlkylating agents and bevacizumab are both first-line chemotherapeutic options for the treatment of glioblastoma; however, their mechanisms of action differ substantially. This study aimed to compare the safety profiles of these two drug classes in the treatment of glioblastoma to inform cl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1595642/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850135147045715968 |
|---|---|
| author | Zhizhao Qu Zhizhao Qu Jiajia Zhao Liu Yang Yuanwei Fu Rui Bai Jinchuan Li Hongqin Wang |
| author_facet | Zhizhao Qu Zhizhao Qu Jiajia Zhao Liu Yang Yuanwei Fu Rui Bai Jinchuan Li Hongqin Wang |
| author_sort | Zhizhao Qu |
| collection | DOAJ |
| description | ObjectiveAlkylating agents and bevacizumab are both first-line chemotherapeutic options for the treatment of glioblastoma; however, their mechanisms of action differ substantially. This study aimed to compare the safety profiles of these two drug classes in the treatment of glioblastoma to inform clinical decision-making.MethodsAdverse events reported between the first quarter of 2004 and the fourth quarter of 2023 were analyzed using data from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis was employed to assess and compare the AE signals associated with bevacizumab and alkylating agents.ResultsIn the context of glioblastoma treatment, 3,323 adverse reports were associated with bevacizumab, 5,283 with temozolomide, and 427 with lomustine. The most frequently reported AEs for bevacizumab were fatigue (n = 276), hypertension (n = 220), and headache (n = 199). Compared to temozolomide, bevacizumab was more strongly associated with “vascular disorders,” “renal and urinary disorders,” and “hypertension.” Notably, bevacizumab appeared to offer a potential safety advantage with respect to hematological adverse events.ConclusionOur analysis indicates that bevacizumab exhibits a distinct safety profile compared to alkylating agents, particularly demonstrating a lower incidence of hematological adverse events. Further prospective studies are warranted to validate these findings and to elucidate the underlying mechanisms responsible for the observed adverse events. |
| format | Article |
| id | doaj-art-6e81c9d9cfaa405f88b9bee074212bfb |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-6e81c9d9cfaa405f88b9bee074212bfb2025-08-20T02:31:30ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15956421595642Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently?Zhizhao Qu0Zhizhao Qu1Jiajia Zhao2Liu Yang3Yuanwei Fu4Rui Bai5Jinchuan Li6Hongqin Wang7Department of Neurosurgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaGraduate School, Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Neurology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Neurosurgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Neurosurgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Neurosurgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Neurosurgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaObjectiveAlkylating agents and bevacizumab are both first-line chemotherapeutic options for the treatment of glioblastoma; however, their mechanisms of action differ substantially. This study aimed to compare the safety profiles of these two drug classes in the treatment of glioblastoma to inform clinical decision-making.MethodsAdverse events reported between the first quarter of 2004 and the fourth quarter of 2023 were analyzed using data from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis was employed to assess and compare the AE signals associated with bevacizumab and alkylating agents.ResultsIn the context of glioblastoma treatment, 3,323 adverse reports were associated with bevacizumab, 5,283 with temozolomide, and 427 with lomustine. The most frequently reported AEs for bevacizumab were fatigue (n = 276), hypertension (n = 220), and headache (n = 199). Compared to temozolomide, bevacizumab was more strongly associated with “vascular disorders,” “renal and urinary disorders,” and “hypertension.” Notably, bevacizumab appeared to offer a potential safety advantage with respect to hematological adverse events.ConclusionOur analysis indicates that bevacizumab exhibits a distinct safety profile compared to alkylating agents, particularly demonstrating a lower incidence of hematological adverse events. Further prospective studies are warranted to validate these findings and to elucidate the underlying mechanisms responsible for the observed adverse events.https://www.frontiersin.org/articles/10.3389/fphar.2025.1595642/fulltemozolomidebevacizumabalkylating agentglioblastomaFAERSsafety profile |
| spellingShingle | Zhizhao Qu Zhizhao Qu Jiajia Zhao Liu Yang Yuanwei Fu Rui Bai Jinchuan Li Hongqin Wang Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently? Frontiers in Pharmacology temozolomide bevacizumab alkylating agent glioblastoma FAERS safety profile |
| title | Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently? |
| title_full | Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently? |
| title_fullStr | Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently? |
| title_full_unstemmed | Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently? |
| title_short | Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently? |
| title_sort | comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management what have we learned recently |
| topic | temozolomide bevacizumab alkylating agent glioblastoma FAERS safety profile |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1595642/full |
| work_keys_str_mv | AT zhizhaoqu comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently AT zhizhaoqu comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently AT jiajiazhao comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently AT liuyang comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently AT yuanweifu comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently AT ruibai comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently AT jinchuanli comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently AT hongqinwang comparativesafetyanalysisofbevacizumabandalkylatingagentinglioblastomamanagementwhathavewelearnedrecently |